Autopsy report · NCT00566462

Assessment of Perampanel (E2007) on Synaptic Dopamine in Mild-moderate PD Patients: A Pilot Study With [^123I]-IBZM SPECT

“Study stopped due to lack of efficacy.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month after it had already started.
• Ran for about 1 year 2 months before it stopped.
• 1 participant enrolled.
• Results were posted on the registry 4 years 1 month after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Eisai Inc.

Sponsor type

Industry

Conditions

Parkinson's Disease

Interventions

perampanel; placebo

Participants

1

Sites

3

Countries

United States

Trials that died the same way

• A Trial of Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy Immunosuppression
  “Study stopped due to lack of efficacy \& funding.” (95% match in meaning)
• Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM
  “The study was terminated due to lack of efficacy.” (91% match in meaning)
• A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
  “The study was early terminated due to lack of efficacy.” (91% match in meaning)
• Dasatinib in Polycythemia Vera
  “This study was terminated due to lack of efficacy.” (91% match in meaning)
• A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration
  “This study was terminated due to a lack of efficacy.” (90% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.